PMC:7204657 / 172-348 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"23","span":{"begin":141,"end":149},"obj":"Species"},{"id":"27","span":{"begin":90,"end":101},"obj":"Chemical"},{"id":"32","span":{"begin":71,"end":79},"obj":"Disease"},{"id":"33","span":{"begin":132,"end":140},"obj":"Disease"}],"attributes":[{"id":"A23","pred":"tao:has_database_id","subj":"23","obj":"Tax:9606"},{"id":"A27","pred":"tao:has_database_id","subj":"27","obj":"MESH:C502936"},{"id":"A32","pred":"tao:has_database_id","subj":"32","obj":"MESH:C000657245"},{"id":"A33","pred":"tao:has_database_id","subj":"33","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":", in the treatment of cytokine release syndrome associated with severe COVID-19. Although tocilizumab may be beneficial in selected COVID-19 patients with a counterproductive h"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T3","span":{"begin":22,"end":30},"obj":"Body_part"}],"attributes":[{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":", in the treatment of cytokine release syndrome associated with severe COVID-19. Although tocilizumab may be beneficial in selected COVID-19 patients with a counterproductive h"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T3","span":{"begin":71,"end":79},"obj":"Disease"},{"id":"T4","span":{"begin":132,"end":140},"obj":"Disease"}],"attributes":[{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":", in the treatment of cytokine release syndrome associated with severe COVID-19. Although tocilizumab may be beneficial in selected COVID-19 patients with a counterproductive h"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T4","span":{"begin":155,"end":156},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":", in the treatment of cytokine release syndrome associated with severe COVID-19. Although tocilizumab may be beneficial in selected COVID-19 patients with a counterproductive h"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T4","span":{"begin":90,"end":101},"obj":"Chemical"}],"attributes":[{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"}],"text":", in the treatment of cytokine release syndrome associated with severe COVID-19. Although tocilizumab may be beneficial in selected COVID-19 patients with a counterproductive h"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T2","span":{"begin":22,"end":47},"obj":"Phenotype"}],"attributes":[{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0033041"}],"text":", in the treatment of cytokine release syndrome associated with severe COVID-19. Although tocilizumab may be beneficial in selected COVID-19 patients with a counterproductive h"}